Cargando…
Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa
Cytology remains the mainstay of cervical cancer screening in South Africa (SA), however false negative rates are 25–50%. In contrast, human papillomavirus (HPV) screening techniques have higher sensitivity for cervical cancer precursors. The cobas® 4800 HPV test detects pooled high-risk HPV types a...
Autores principales: | Dreyer, Greta, Maske, Christopher, Stander, Marthinus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738657/ https://www.ncbi.nlm.nih.gov/pubmed/31509545 http://dx.doi.org/10.1371/journal.pone.0221495 |
Ejemplares similares
-
Cobas 4800 HPV detection in cervical samples of Polish women
por: Smolarz, Beata, et al.
Publicado: (2019) -
Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
por: Liu, Stephanie S., et al.
Publicado: (2022) -
Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
por: Cook, Darrel A., et al.
Publicado: (2015) -
A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening
por: Hwang, Sang-Hyun, et al.
Publicado: (2018) -
HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system
por: Frayle, Helena, et al.
Publicado: (2019)